Journal
INFLAMMATORY BOWEL DISEASES
Volume 25, Issue 12, Pages 1896-1905Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ibd/izz059
Keywords
inflammatory bowel disease; crohn's disease; ulcerative colitis; early biologic therapy; top-down therapy
Categories
Funding
- NIDDK NIH HHS [K23 DK111995] Funding Source: Medline
Ask authors/readers for more resources
The goals for treatment of inflammatory bowel diseases (IBDs) are changing from elimination of symptoms toward complete disease control-a process that demands both clinical and endoscopic remission. This new IBD treatment paradigm has been shifting from a conventional step-up approach toward a more top-down early intervention treatment strategy. Recent studies suggest that the use of biologic agents, specifically those targeting tumor necrosis factor alpha, earlier in the treatment course improves patient outcomes and can prevent progression to irreversible bowel damage. Although the strategy of early intervention has accumulating evidence in Crohn's disease, there is less evidence supporting its impact in ulcerative colitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available